Artificial Intelligence and Patient-centric Approaches to Advance Pharmaceutical Innovation
Kenneth I. Kaitin, PhD, Tufts Center for the Study of Drug Development
Clin Ther. 2019 Aug; 41(8):1406-1407. doi: 10.1016/j.clinthera.2019.06.014. Epub 2019 Jul 25.
PMID: 31353132 | DOI: 10.1016/j.clinthera.2019.06.014
Since the start of this century, stunning advances in our understanding of the pathophysiology and genetic determinants of a host of diseases that currently lack adequate and effective treatments have opened the door to new avenues of biomedical innovation. In many cases, however, these scientific advances have not translated into the development of new and better medicines, especially for a number of diseases that take an exacting toll in morbidity and mortality, including heart disease, stroke, diabetes, obesity, and dementia.